AlphaVax announced today the initiation of a Chlamydia vaccine program based on its alphavirus vector platform technology. Genital chlamydial infections, caused by the bacterium Chlamydia trachomatis, have been shown to be the most prevalent bacterial sexually transmitted disease worldwide...

AlphaVax, Inc. recently received notification from the National Institute of Allergies and Infectious Diseases (NIAID), one of the granting institutes of the National Institutes of Health (NIH), that it has been awarded a second grant to continue development of a smallpox vaccine based on AlphaVax’s proprietary vector platform...

AlphaVax, Inc. announced today an initial analysis of data from a Phase I clinical trial of a cytomegalovirus (CMV) vaccine that is based on its platform alphavirus replicon vector technology...